maternal pbpk model Search Results


pbpk feto maternal models  (Feto Maternal and GenetYX Center)
90
Feto Maternal and GenetYX Center pbpk feto maternal models
The best practice approach to <t>physiologically</t> <t>based</t> <t>pharmacokinetic</t> <t>(PBPK)</t> model development and application in pregnant women. ADME, absorption, distribution, metabolism, and excretion; DDI, drug‐to‐drug interaction; PK, pharmacokinetic.
Pbpk Feto Maternal Models, supplied by Feto Maternal and GenetYX Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maternal+pbpk+model/pbpk+feto+maternal+models/pmc05824116-136-3-4
Average 90 stars, based on 1 article reviews
pbpk feto maternal models - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
maternal fetal pbpk model in simcyp  (Simcyp)
86
Simcyp maternal fetal pbpk model in simcyp
The best practice approach to <t>physiologically</t> <t>based</t> <t>pharmacokinetic</t> <t>(PBPK)</t> model development and application in pregnant women. ADME, absorption, distribution, metabolism, and excretion; DDI, drug‐to‐drug interaction; PK, pharmacokinetic.
Maternal Fetal Pbpk Model In Simcyp, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maternal+pbpk+model/fetal+in+maternal+model+pbpk+simcyp/pmc13136160-89-11-15
Average 86 stars, based on 1 article reviews
maternal fetal pbpk model in simcyp - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


The best practice approach to physiologically based pharmacokinetic (PBPK) model development and application in pregnant women. ADME, absorption, distribution, metabolism, and excretion; DDI, drug‐to‐drug interaction; PK, pharmacokinetic.

Journal: CPT: Pharmacometrics & Systems Pharmacology

Article Title: Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations

doi: 10.1002/psp4.12274

Figure Lengend Snippet: The best practice approach to physiologically based pharmacokinetic (PBPK) model development and application in pregnant women. ADME, absorption, distribution, metabolism, and excretion; DDI, drug‐to‐drug interaction; PK, pharmacokinetic.

Article Snippet: We believe that PBPK feto‐maternal models will be highly desirable to support fetal exposure assessment.

Techniques:

A mechanistic framework for applying a physiologically based pharmacokinetic (PBPK) feto‐maternal model for predicting human fetotoxicity risk from preclinical species described in the following steps. (1) Perform fetotoxicity studies in preclinical animals and establish exposure‐toxicity relationships. (2) Construct a coupled feto‐maternal PBPK model that accounts for gestational age related changes in the physiology and placenta to describe the relationship between fetal tissue and systemic concentrations together with maternal systemic concentration. (3) Use the constructed PBPK model to find the toxic doses that can cause feto‐toxic drug levels after accounting for species differences in physiological/biochemical parameters (number of placentas, weight, blood flow, transporters, and enzyme expression). (4) The human PBPK model can also be refined if in vitro and/or in vivo human data are available. (5) The human PBPK model that predicts the systemic exposure in fetus and mother can be used to predict the local fetal tissue concentration. (6) Fetal local tissue concentration can be linked to the predicted toxicity after accounting for any potential species differences in the toxicodynamic model. This figure is adapted from the publication by Abduljalil et al . Conc, concentration; IC50, half‐maximal inhibitory concentration.

Journal: CPT: Pharmacometrics & Systems Pharmacology

Article Title: Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations

doi: 10.1002/psp4.12274

Figure Lengend Snippet: A mechanistic framework for applying a physiologically based pharmacokinetic (PBPK) feto‐maternal model for predicting human fetotoxicity risk from preclinical species described in the following steps. (1) Perform fetotoxicity studies in preclinical animals and establish exposure‐toxicity relationships. (2) Construct a coupled feto‐maternal PBPK model that accounts for gestational age related changes in the physiology and placenta to describe the relationship between fetal tissue and systemic concentrations together with maternal systemic concentration. (3) Use the constructed PBPK model to find the toxic doses that can cause feto‐toxic drug levels after accounting for species differences in physiological/biochemical parameters (number of placentas, weight, blood flow, transporters, and enzyme expression). (4) The human PBPK model can also be refined if in vitro and/or in vivo human data are available. (5) The human PBPK model that predicts the systemic exposure in fetus and mother can be used to predict the local fetal tissue concentration. (6) Fetal local tissue concentration can be linked to the predicted toxicity after accounting for any potential species differences in the toxicodynamic model. This figure is adapted from the publication by Abduljalil et al . Conc, concentration; IC50, half‐maximal inhibitory concentration.

Article Snippet: We believe that PBPK feto‐maternal models will be highly desirable to support fetal exposure assessment.

Techniques: Construct, Concentration Assay, Expressing, In Vitro, In Vivo